Trinity Biotech (TRIB) Total Non-Current Liabilities (2016 - 2024)
Trinity Biotech (TRIB) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $106.4 million as the latest value for Q4 2024.
- Quarterly Total Non-Current Liabilities rose 55.64% to $106.4 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $106.4 million through Dec 2024, up 55.64% year-over-year, with the annual reading at $106.4 million for FY2024, 55.64% up from the prior year.
- Total Non-Current Liabilities hit $106.4 million in Q4 2024 for Trinity Biotech, up from $68.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $106.4 million in Q4 2024 to a low of $18.7 million in Q4 2021.
- Historically, Total Non-Current Liabilities has averaged $75.2 million across 5 years, with a median of $76.9 million in 2022.
- Biggest five-year swings in Total Non-Current Liabilities: tumbled 82.26% in 2021 and later skyrocketed 310.94% in 2022.
- Year by year, Total Non-Current Liabilities stood at $105.6 million in 2020, then crashed by 82.26% to $18.7 million in 2021, then soared by 310.94% to $76.9 million in 2022, then dropped by 11.17% to $68.3 million in 2023, then surged by 55.64% to $106.4 million in 2024.
- Business Quant data shows Total Non-Current Liabilities for TRIB at $106.4 million in Q4 2024, $68.3 million in Q4 2023, and $76.9 million in Q4 2022.